|
Group
|
Day 4
|
Day 5
|
Day 6
|
Day 7
|
|---|
|
Normal
|
0.00 ± 0.00
|
0.00 ± 0.00
|
0.00 ± 0.00
|
0.00 ± 0.00
|
|
Negative control
|
2.87 ± 0.59
|
1.26 ± 0.31
|
0.25 ± 0.16
|
0.00 ± 0.00
|
|
Loperamide
|
1.51 ± 0.52 *
|
0.11 ± 0.09 **
|
0.00 ± 0.00*
|
0.00 ± 0.00
|
|
GOS 5%
|
2.06 ± 0.24 a
|
0.22 ± 0.24 **
|
0.00 ± 0.00*
|
0.00 ± 0.00
|
|
GOS 10%
|
1.64 ± 0.41 *a
|
0.15 ± 0.04 **
|
0.00 ± 0.00*
|
0.00 ± 0.00
|
|
GOS 15%
|
1.18 ± 0.33 **b
|
0.06 ± 0.04 **
|
0.00 ± 0.00*
|
0.00 ± 0.00
|
- Normal, the uninfected-untreated control. Negative control, the infected-untreated control. Loperamide, the infected group with Loperamide-treatment (10 mg/kg). The 5, 10 and 15% GOS were the infected groups treated with corresponding concentration of GOS at a dose of 10 mL/kg, respectively. * P < 0.05 and ** P < 0.01, compared with the negative control. a, b Different letters indicate significant differences existed among the three GOS groups (P < 0.05). Data are presented as mean ± S.E.M. n = 16
